Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 21;29(157):200014.
doi: 10.1183/16000617.0014-2020. Print 2020 Sep 30.

Prevalence of α1-antitrypsin PiZZ genotypes in patients with COPD in Europe: a systematic review

Affiliations

Prevalence of α1-antitrypsin PiZZ genotypes in patients with COPD in Europe: a systematic review

Ignacio Blanco et al. Eur Respir Rev. .

Abstract

The percentage of α1-antitrypsin protease inhibitor ZZ (PiZZ) genotypes in patients with COPD is controversial, with large differences among various studies. We aimed to estimate the prevalence of PiZZ in COPD patients from 20 European countries with available data, according to the number of PiZZ and COPD individuals in each country.A systematic review was conducted to select European countries with reliable data on the prevalence of PiZZ and COPD. We created a database with the following data: 1) total population and population aged ≥40 years according to the Eurostat database; 2) number and 95% CI of PiZZ patients aged ≥40 years; 3) application of a conversion factor of genetic penetrance of 60%; 4) number of COPD individuals, with 95% CI, aged ≥40 years; and 5) calculation of the PiZZ/COPD ratio. Finally, results were presented using an Inverse Distance Weighted Interpolation map.We found 36 298 (95% CI 23 643-56 594) PiZZ individuals at high risk and 30 849 709 (95% CI 21 411 293-40 344 496) COPD patients, with a PiZZ/COPD ratio of 0.12% (range 0.08-0.24%), and a prevalence of 1 out of 408 in Northern, 1 out of 944 in Western, 1 out of 1051 in Central, 1 out of 711 in Southern, and 1 out of 1274 in Eastern Europe.These data may be useful to plan strategies for future research and diagnosis, and to rationalise the available therapeutic resources.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: I. Blanco has nothing to disclose. Conflict of interest: I. Diego has nothing to disclose. Conflict of interest: P. Bueno has nothing to disclose. Conflict of interest: S. Pérez-Holanda has nothing to disclose. Conflict of interest: F. Casas-Maldonado has nothing to disclose. Conflict of interest: M. Miravitlles reports speakers fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, Zambon, Sandoz, CSL Behring, Grifols and Novartis; consultancy fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, CSL Behring, Laboratorios Esteve, Ferrer, Mereo Biopharma, Verona Pharma, Kamada, TEVA, Sanofi, pH Pharma, Novartis and Grifols; grants from GlaxoSmithKline and Grifols, outside the submitted work.

Figures

FIGURE 1
FIGURE 1
Map of inverse distance weighted interpolation showing the PiZZ/COPD ratio (1/x) in 20 European countries. PiZZ refers to the number of individuals aged ≥40years, after applying a correction factor of 60% of genetic penetrance. COPD refers to the total number of patients aged ≥40years from each country. The colour scale corresponds to the prevalence of PiZZ in the total COPD (1/x) of each country. Countries without data are shaded pale green. Unpopulated or sparsely populated regions (with less than two inhabitants per square kilometre) are shaded white. PiZZ: α1-antitrypsin protease inhibitor ZZ. n=total number points with known values in IDW interpolation (12 for the current map); p=power parameter (p=2 for the current map); res=resolution (0.05 for the present map).

References

    1. Hutchison DCS. Αlpha1-antitrypsin in Europe: geographical distribution of Pi types S and Z. Respir Med 1998; 92: 367–377. doi:10.1016/S0954-6111(98)90278-5 - DOI - PubMed
    1. American Thoracic Society, European Respiratory Society . American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003; 168: 818–900. doi:10.1164/rccm.168.7.818 - DOI - PubMed
    1. Lomas DA, Evans DL, Finch JT, et al. . The mechanism of Z α1 antitrypsin accumulation in the liver. Nature 1992; 357: 605–607. doi:10.1038/357605a0 - DOI - PubMed
    1. Piras B, Ferrarotti I, Lara B, et al. . Characteristics of Italian and Spanish patients with alpha-1-antitrypsin deficiency: Identifying clinical phenotypes. Eur Respir J 2013; 42: 54–64. doi:10.1183/09031936.00104712 - DOI - PubMed
    1. McElvaney NG, Stoller JK, Buist AS, et al. . Baseline characteristics of enrolees in the National Heart, Lung and Blood Institute Registry of α1-antitrypsin deficiency. Chest 1997; 111: 394–403. doi:10.1378/chest.111.2.394 - DOI - PubMed

Publication types

MeSH terms